8 take­aways from Bio­gen’s Q1 up­date: A ‘dif­fi­cult’ launch for Leqem­bi, a $103M vouch­er and a fo­cus on new li­cens­ing deals

Bio­gen’s lead­ers de­fend­ed their Ei­sai-part­nered Leqem­bi dur­ing a first-quar­ter earn­ings up­date on Wednes­day, say­ing the Alzheimer’s treat­ment is on a path to greater up­take as more pa­tients start­ed treat­ment last month.

The com­pa­ny is in the midst of re­set­ting its busi­ness, mak­ing hun­dreds of cuts to its work­force in re­cent quar­ters and re­shap­ing its pipeline last year. Now, Bio­gen said it’s on more sol­id foot­ing for the fu­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER